ReviewInnate immunity2019
Epigenetic and metabolic programming of innate immunity in sepsis.
Review in Innate immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Dysregulation of Neutrophil-Endothelial Communication in Sepsis: Mechanisms and Therapeutic Perspectives.Cells · 2026Review
- Metabolic and post-translational modifications in sepsis-associated immune dysfunction: a conceptual framework.Frontiers in immunology · 2026Review
- Macrophage reprogramming and functional plasticity in sepsis.Frontiers in immunology · 2026Review
- The Epigenetics of Sepsis: How Gene Modulation Shapes Outcomes.Biomedicines · 2025Review
- Molecular insights and clinical implications of DNA methylation in sepsis-associated acute kidney injury: a narrative review.BMC nephrology · 2025Review
- Single-cell profiling reveals a conserved role for hypoxia-inducible factor signaling during human craniotomy infection.Cell reports. Medicine · 2024Article
- TCA metabolism regulates DNA hypermethylation in LPS andProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Distinct functional neutrophil phenotypes in sepsis patients correlate with disease severity.Frontiers in immunology · 2024Article
- Epigenome-wide DNA methylation profiling in septic and non-septic patients with similar infections: potential use as sepsis biomarkers.Frontiers in cellular and infection microbiology · 2024Article
- Influence of maternal nutrition and one-carbon metabolites supplementation on bovine antimicrobial peptides in fetal and maternal tissues.Frontiers in veterinary science · 2024Article
- Potential biomarker for diagnosis and therapy of sepsis: Lactylation.Immunity, inflammation and disease · 2023Review
- Maternal consumption of a high-fat diet modulates the inflammatory response in their offspring, mediated by the M1 muscarinic receptor.Frontiers in immunology · 2023Article
- Inhibition of miR-146a Expression and Regulation of Endotoxin Tolerance by Rhesus Theta-Defensin-1.Mediators of inflammation · 2023Article
- Sepsis, pyruvate, and mitochondria energy supply chain shortage.Journal of leukocyte biology · 2022Review
- Identification of key biomarkers in neonatal sepsis by integrated bioinformatics analysis and clinical validation.Heliyon · 2022Article
- [New aspects of perioperative organ protection].Die Anaesthesiologie · 2022Review
- Exploring epigenetic reprogramming during central nervous system infection.Immunological reviews · 2022Review
- BACH1-Hemoxygenase-1 axis regulates cellular energetics and survival following sepsis.Free radical biology & medicine · 2022Article
- Dichloroacetate improves systemic energy balance and feeding behavior during sepsis.JCI insight · 2022Article
- New insights of necroptosis and immune infiltration in sepsis-induced myocardial dysfunction from bioinformatics analysis through RNA-seq in mice.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sepsis, the 10th leading cause of death, is the most expensive condition in the United States. The immune response in sepsis transitions from hyperinflammatory to a hypoinflammatory and immunosuppressive phase; individual variations regarding timing and overlap between hyper- and hypoinflammation exist in a number of patients. While one third of the sepsis-related deaths occur during hyperinflammation, majority of the sepsis-mortality occurs during the hypoinflammatory phase. Currently, no phase-specific molecular-based therapies exist to treat sepsis. Coordinated epigenetic and metabolic perturbations orchestrate this shift from hyper- to hypoinflammation in innate immune cells during sepsis. These epigenetic and metabolic changes during sepsis progression and therapeutic opportunities they pose are described in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.